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Background: Severe malnutrition is frequently complicated by sepsis, leading to high case fatality. Oral cipro-
floxacin is a potential alternative to the standard parenteral ampicillin/gentamicin combination, but its phar-
macokinetics in malnourished children is unknown.
Methods: Ciprofloxacin (10 mg/kg, 12 hourly) was administered either 2 h before or up to 2 h after feeds to
Kenyan children hospitalized with severe malnutrition. Four plasma ciprofloxacin concentrations were
measured over 24 h. Population analysis with NONMEM investigated factors affecting the oral clearance (CL)
and the oral volume of distribution (V). Monte Carlo simulations investigated dosage regimens to achieve a
target AUC0 – 24/MIC ratio of ≥125.
Results: Data comprised 202 ciprofloxacin concentration measurements from 52 children aged 8–102 months.
Absorption was generally rapid but variable;Cmax ranged from 0.6 to 4.5 mg/L. Datawere fitted bya one-compartment
model with first-order absorption and lag. The parameters were CL (L/h)¼42.7 (L/h/70 kg)×[weight (kg)/
70]0.75×[1+0.0368 (Na+ – 136)]×[1 – 0.283 (high risk)] and V (L)¼372×(L/70 kg)×[1+0.0291 (Na+ – 136)]. Esti-
mates of AUC0 – 24 ranged from 8 to 61 mg.h/L. The breakpoint for Gram-negative organisms was ,0.06 mg/L
with doses of 20 mg/kg/day and ,0.125 mg/L with doses of 30 or 45 mg/kg/day. The cumulative fraction of
response with 30 mg/kg/day was ≥80% for Escherichia coli, Klebsiella pneumoniae and Salmonella species, but
,60% for Pseudomonas aeruginosa.
Conclusions: An oral ciprofloxacin dose of 10 mg/kg three times daily (30 mg/kg/day) may be a suitable alterna-
tive antibiotic for the management of sepsis in severely malnourished children. Absorption was unaffected by the
simultaneous administration of feeds.
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Introduction
Severe malnutrition remains a common cause of admission to
hospital in less-developed countries. Many centres, particularly
in Africa, report poor outcome despite adherence to rec-
ommended treatment guidelines.1 – 4 The children at the greatest
risk of fatal outcome are those with Gram-negative septicaemia,
constituting 48%–55% of invasive bacterial pathogens, and
those admitted with diarrhoea and/or shock.5,6 Changes in the
intestinal mucosal integrity and gut microbial balance occur in
severe malnutrition,7 resulting in treatment failure and adverse
clinical outcome.8 The higher prevalence of gut barrier
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dysfunction in children with severe malnutrition may have impor-
tant effects on the absorption of antimicrobials and their bioa-
vailability, and therefore may limit choices for the delivery of
antimicrobial medication.
Children with severe and complicated malnutrition routinely
receive broad-spectrum parenteral antibiotics.9 In vitro antibiotic
susceptibility testing indicates that up to 85% of organisms are
fully susceptible to the first-line treatment, parenteral ampicillin
and gentamicin, recommended by the WHO for children with
severe and complicated malnutrition.4 Pharmacokinetic studies
have demonstrated satisfactory plasma concentrations of
these commonly used antibiotics.10 However, in vitro resistance
has been associated with later deaths, and the current second-
line antibiotic (chloramphenicol) was found to offer little advan-
tage over the ampicillin and gentamicin combination.4
Fluoroquinolones are effective against most Gram-negative
organisms and have activity against Gram-positive organisms,
especially when given in combination.11 The quinolones are
used in the treatment of serious bacterial infections in adults;
however, their use in children has been restricted due to concerns
about potential cartilage damage.12 Nevertheless, quinolones are
increasingly prescribed for paediatric patients. Ciprofloxacin is
licensed in children .1 year of age for pseudomonal infections
in cystic fibrosis, for complicated urinary tract infections, and for
the treatment and prophylaxis of inhalation anthrax.13 When
the benefits of treatment outweigh the risks, ciprofloxacin is
also licensed in the UK for children.1 year of age with severe res-
piratory tract and gastrointestinal system infection.14 In its many
years of clinical use, ciprofloxacin has been found effective, even
with oral administration, owing to its bioavailability of 70%.15
However, few studies have evaluated the population pharmacoki-
netics of ciprofloxacin in children,16 – 18 and no studies have been
conducted in severe malnutrition.
For the treatment of Gram-negative infection, common in
severe malnutrition, pragmatic and cost-effective treatments are
needed to improve outcome. Since intravenous formulations of
fluoroquinolones are very expensive, they are rarely used in
resource-poor settings. Oral formulations would appear to be the
best option in patients who are able to ingest and adequately
absorb medication. The aims of this study were to determine the
pharmacokinetic profile of oral ciprofloxacin given at a dose of
10 mg/kg twice daily to children admitted to hospital with severe
malnutrition, to develop a population model to describe the phar-
macokinetics of ciprofloxacin in this patient group, and to use
Monte Carlo simulation techniques to investigate potential relation-
ships between dosage regimens and antimicrobial efficacy.
Methods
Patients
The study was conducted at Kilifi District Hospital, Kenya. All children
admitted to the ward were examined by a member of the clinical research
team. Between July 2008 and February 2009, children .6 months of age
were assessed for eligibility for the study. Eligible children had severe mal-
nutrition, defined as one of the following: weight-for-height z-score (WHZ)
of ≤3; mid-upper arm circumference of ,11 cm; or the presence of bilat-
eral pedal oedema (kwashiorkor). Children with evidence of intrinsic renal
disease (creatinine concentration .300 mmol/L and hypertension or
hyperkalaemia) were excluded. No cases had coexisting chronic bone or
joint disease, or concurrently prescribed antacids, ketoconazole,
theophylline or corticosteroids. The study was explained to the child’s
parent or guardian in their usual language and written informed consent
was obtained. The Kenya Medical Research Institute/National Ethical
Review Committee approved the study.
Baseline laboratory tests included a full blood count, blood film for
malaria parasites, plasma creatinine, electrolytes, plasma glucose,
blood gases, blood culture and HIV rapid antibody test. Blood cultures
were processed by a BACTEC 9050 instrument (Becton Dickinson, NJ,
USA). Children were treated according to the standard WHO manage-
ment guidelines for severe malnutrition. These include nutritional
support with a special milk-based formula (F75 and F100), multivitamin
and multimineral supplementation and reduced sodium oral rehydration
solution (RESOMAL) for children with diarrhoea (.3 watery stools/day). At
admission, all children were prescribed parenteral ampicillin (50 mg/kg
four times a day) and intramuscular gentamicin (7.5 mg/kg once daily)
for 7 days. These were revised, when indicated by the child’s clinical con-
dition or culture results. Other fluoroquinolones were not prescribed
during the study period, since they were not routinely available.
Study procedures
Ciprofloxacin concentration–time profiles were obtained during two study
periods. In the initial study period, children were given the ciprofloxacin
either 2 h before or 2 h after they had their nutritional milks or meal. In
this first period of the study (n¼36), an equal number of patients were
included in three subgroups: low risk; intermediate risk; and high risk of
fatality. The stratification of risk was based on a previous report.4 High
risk included children presenting with one of the following: depressed con-
scious state; bradycardia (heart rate ,80 beats per minute); evidence of
shock (capillary refill time ≥2 seconds, temperature gradient or weak
pulse); or hypoglycaemia (blood glucose ,3 mmol/L). Intermediate risk
included any one of: deep ‘acidotic’ breathing; signs of severe dehydration
(plus diarrhoea); lethargy; hyponatraemia (sodium ,125 mmol/L); or
hypokalaemia (potassium ,2.5 mmol/L). Children with low risk had
none of these factors. In the second study period (n¼16), the drug was
administered at the time they received nutritional feeds and did not
have any risk stratification.
Drug administration and blood sampling
Participants received witnessed doses of oral ciprofloxacin (10 mg/kg
body weight), i.e. a standard treatment dose, every 12 h for 48 h, starting
on the day of admission. Routine antimicrobials were given simul-
taneously as the empirical treatment for invasive infections. Since oral
suspensions are not available locally, ciprofloxacin tablets (BactifloxTM
250 mg, Mepha Pharma AG, Switzerland) were reformulated into an
aqueous suspension by the study pharmacist. A separate tablet was
used to prepare each individual dose and the suspension was then
used immediately. Individual doses were measured by the pharmacist
under the observation of the trial nurse, according to the patient’s
body weight. This approach has been used and reported previously.19
Children were allocated, using a computer-generated randomization
list, to one of three blood sampling schedules: Group A at 2, 4, 8 and
24 h; Group B at 3, 5, 9 and 12 h; and Group C at 1, 3, 6 and 10 h. Children
in each of the risk categories were evenly allocated across the sampling
schedules. To minimize discomfort to the child, blood sampling for the
measurement of ciprofloxacin concentrations was through an in situ
cannula, which was only used for this purpose. At each timepoint, a
venous blood sample (0.5 mL) was collected into a lithium heparin tube,
centrifuged, and the plasma separated and stored in cryovials at 2208C
until analysed. A rapid, selective and sensitive HPLC method coupled
with fluorescence detection was used to determine the concentration of
ciprofloxacin in the plasma samples.20 The intra- and interassay impreci-
sions of the HPLC method were ,8.0%, and accuracy values ranged
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from 93% to 105% for quality control samples at 0.2, 1.8 and 3.6 mg/L.
Calibration curves of ciprofloxacin were linear over the concentration
range of 0.02–4 mg/L, with correlation coefficients ≥0.998.
Pharmacokinetic analysis
Population pharmacokinetic parameter estimates were obtained with
NONMEM version VI using first-order conditional estimation with
interaction.21 Post-processing of the NONMEM results was performed
with Xpose version 4 programmed in R 2.9.2.22,23 Preliminary analyses
found that a one-compartment elimination model adequately
described the concentration–time profiles; absorption was described
using first- and zero-order models with an absorption lag and with a
transit compartment model.24 Relationships between the oral clearance
of ciprofloxacin (CL) and weight, and between the oral volume of
distribution (V) and weight were described using an allometric
approach,25 i.e.
Oral CL (L/h) = CL standard (L/h/70 kg) × [weight (kg)/70]0.75
OralV (L) = V standard (L/70 kg) × [weight (kg)/70]
Between-subject variabilities (BSV) in the pharmacokinetic parameters
were assumed to be log-normally distributed and covariance between
the variabilities in the pharmacokinetic parameters was investigated. A
combined proportional and additive error model was used to describe
the residual error.
A wide range of demographic, biochemical and haematological data
were collected in the course of the study. In addition, creatinine clear-
ance estimates for each patient, according to age range, were calculated
using the equations of Schwarz et al.26,27 Potential relationships between
the clinical and demographic factors and empirical Bayes’ estimates
(individual estimates) of ciprofloxacin oral CL, oral V and absorption
rate were initially examined visually using scatter plots and by general
additive modelling within Xpose.22 Factors identified as potential covari-
ates that might explain variability in ciprofloxacin pharmacokinetics were
then added individually to the population model. A statistically signifi-
cant improvement in the fit of the model to the data was defined as
a reduction in the objective function value (OFV) of ≥3.84 (P ,0.05) in
the forward stepwise analysis. The covariate that produced the greatest
fall in OFV was included first, and then other covariates were added to
and removed from the model in a stepwise manner that included
changing the order of inclusion and removal. Statistical significance
was defined as an increase in OFV of ≥6.63 (P,0.01) when a covariate
was removed. Additional criteria, such as goodness-of-fit plots, the pre-
cision of the parameter estimates, and the ability of covariates to
explain variability in the oral CL, oral V and absorption rate, were also
considered.
The final population model was evaluated in three ways: a bootstrap
sampling procedure with 1000 samples; a prediction-corrected visual
predictive check (pcVPC) based on 1000 simulations; and by examination
of normalized prediction distribution errors (npde) from 1000 simulations.
Both the bootstrapping procedure and the pcVPC were performed using
PsN toolkit;28,29 npde were computed using the software developed by
Brendel et al.30
Time to maximum (Tmax) and maximum concentrations of ciproflox-
acin (Cmax) for each patient were obtained from the raw data and esti-
mated using the individual pharmacokinetic parameter values.
Estimates of steady-state AUC within each dosage interval (AUC12)
and each day (AUC24) were calculated from 12 hourly dose/CLi and
daily dose/CLi, respectively, where CLi are the individual estimates of
oral CL. Individual estimates of the elimination half-life (t1
2
) were
calculated from 0.693×Vi/CLi, where Vi are the individual estimates of
oral V.
Monte Carlo simulations
The final parameters of the population pharmacokinetic model were
used to simulate estimates of oral CL for 10 000 patients using
NONMEM version VI.21 Relevant clinical characteristics (weight and
sodium concentration) were assumed to arise from log-normal distri-
butions with outer limits set to the values observed in the raw data.
The incidence of ‘high risk’ in the simulated dataset was 31%. AUC24 esti-
mates were then determined for each simulated patient from daily
dose/oral CL. Simulations were performed for three dosage regimens:
20 mg/kg/day (current daily dosage regimen); 30 mg/kg/day; and
45 mg/kg/day. For evaluation of these dosage regimens, MIC values
were chosen across the range 0.03–8 mg/L. The probability of target
attainment (PTA) was defined as the probability that the target
AUC0 – 24/MIC ratio was achieved at each MIC. Target AUC0 – 24/MIC
ratios of ≥125 were used.31 For each ciprofloxacin regimen, the highest
MIC at which the PTA was ≥90% was defined as the pharmacokinetic/
pharmacodynamic susceptible breakpoint.
A second analysis was conducted using the MIC distributions for
Escherichia coli, Pseudomonas aeruginosa, Salmonella spp. and Klebsiella
pneumoniae derived from the database of the European Committee on
Antimicrobial Susceptibility Testing.32 These MIC distributions were
extracted from 17877 strains of E. coli, 27825 strains of P. aeruginosa,
5898 strains of K. pneumoniae and 1733 strains of Salmonella spp. The
cumulative fraction of response (CFR) was used to estimate the overall
response of pathogens to ciprofloxacin with each of the three dosage
regimens. This estimate accounts for the variability of drug exposure in
the population and the variability in the MIC combined with the distri-
butions of MICs for the pathogens. For each MIC, the fraction of simulated
patients who met the pharmacodynamic target (AUC0 – 24/MIC≥125)
was multiplied by the fraction of the distribution of microorganisms for
each MIC. The CFR was calculated as the sum of fraction products over
all MICs.
Results
Participants and admission clinical characteristics
Of the 90 children with severe malnutrition admitted during the
study period, 52 were enrolled into the study. Twelve who ful-
filled the entry criteria declined to give consent, in four intrave-
nous access was not possible and 22 were excluded due to
completion of recruitment to a specific subgroup. The demo-
graphic and clinical characteristics of the patients included in
the study are summarized in Table 1. Median age [interquartile
range (IQR)] was 23 months (15–33 months), 29 (56%) were
male, oedema (defining kwashiorkor) was present in 24 patients
(46%) and eight (15%) children were HIV antibody positive. The
median weight (IQR) was 6.9 kg (6.1–8.4 kg). The estimated
creatinine clearance ranged from 5 to 128.7 mL/min/1.73 m2;
only one patient had severe renal impairment. According to the
risk stratification, mortality was 21%, 12% and 0% in the high-
risk, intermediate-risk and low-risk groups, respectively. Bacter-
aemia was present in six children; three had E. coli, two had
S. pneumoniae and one had K. pneumoniae. The isolates were
tested against ampicillin, gentamicin, ciprofloxacin, chloramphe-
nicol and ceftriaxone. The K. pneumoniae isolate was resistant to
ampicillin only, while one E. coli isolate was resistant to all of the
tested antibiotics. One S. pneumoniae isolate was resistant to
ampicillin and had intermediate susceptibility to ciprofloxacin.
Ciprofloxacin was well tolerated and there were no adverse
events reported with its use.
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Pharmacokinetic data analysis
A total of 202 plasma ciprofloxacin concentration measurements
were available, with a median of 4 (range 2–4) measurements
per patient. Individual concentration–time profiles are presented
in Figure 1. Tmax ranged from 1 to 5 h (median 3 h) after the
dose, and in 69% of patients Cmax was observed within 1–3 h.
Cmax ranged from 0.6 to 4.5 mg/L with a median of 1.7 mg/L.
Cmax was .1 mg/L and .2 mg/L in 77% and 31% of patients,
respectively. Trough concentrations at 12 h after the first dose
were available from 17 patients and ranged from 0.1 to
0.7 mg/L with a median of 0.3 mg/L.
Both the first-order with lag and the transit compartment
absorption models provided good fits of the population and indi-
vidual concentration–time profiles. Since the transit compart-
ment model was unstable during validation procedures and
provided little improvement in the overall fit of the data, the
first-order model with lag was used for covariate model develop-
ment. The transit compartment model was tested again with
the final covariate model, but offered no clear advantage.
Plots of individual estimates of oral CL and oral V against the
measured and derived clinical and demographic data identified
potential relationships between oral CL and risk category,
serum sodium concentration, serum potassium concentration,
feeding status, shock and dehydration, and between oral V and
risk category, serum sodium concentration, shock, dehydration,
diarrhoea and vomiting. These factors all achieved small, but
statistically significant, reductions in the OFV when included indi-
vidually in the population model for oral CL. The biggest
reductions occurred with sodium concentration (6.24) and the
high-risk category (6.05). When these factors were combined,
the OFV fell by a further 14.46 points. BSV in oral CL fell from
49.8% with the base model to 38.1% with the covariate
model. No additional factors reduced the variability in oral CL,
but a further reduction in OFV and BSV in oral V (from 48.4%
to 43.0%) was obtained when sodium concentration was
added to the model for oral V. Although the inclusion of bicar-
bonate concentration as a factor influencing the absorption
rate constant (ka) produced a statistically significant reduction
in OFV, it did not reduce BSV in ka and was therefore excluded.
The final population model parameters and bootstrap estimates
are presented in Table 2 and summarized below.
Oral CL (L/h) = 42.7 (L/h/70 kg) × [weight (kg)/70]0.75
× [1 + 0.0368 (Na+−136)] × [1−0.283 (high risk)]
OralV (L) = 372 × (L/70 kg) × [1 + 0.0291(Na+−136)]
ka = 2.97/h, absorption lag = 0.74 h
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Figure 1. Ciprofloxacin concentration measurements in 52 children with
malnutrition following oral doses of 10 mg/kg. Samples were measured
after the first dose in all patients and after a second dose 12 h later in
16 patients.
Table 1. Summary of the demographic and clinical characteristics of
the patients who participated in the study
Characteristic
Number (%)/median
(range)
Interquartile
range
Male/female 29/23 (56/44)
Oedema 24 (46)
HIV positive 8 (15)
Age (months) 23 (8–102) 15–33
Weight (kg) 6.9 (4.1–14.5) 6.1–8.4
Height (cm) 75.4 (58.5–114.4) 70.1–81.4
MUAC (cm) 11 (7.7–14.3) 10–12
WHZ 23.26 (25.69–0.04) 23.67 to 22.48
Vomiting 15 (29)
Shock 7 (13)
Dehydration 25 (48)
Low risk 22 (42)
Intermediate risk 14 (27)
High risk 16 (31)
White blood cell (×106/L)
(6–17.5)
13.3 (5.5–84.4) 10.3–17.1
Haemoglobin (g/dL)
(9–14)
9.0 (2.1–12.8) 7.2–9.8
Platelets (×106/L)
(150–400)
309 (16–1369) 210–451
Sodium (mmol/L)
(138–145)
136 (120–160) 131–138
Potassium (mmol/L)
(3.5–5)
3.1 (1.2–5.1) 2.3–4.1
Glucose (mmol/L) (2.8–5) 4 (0.4–11.4) 2.8–4.7
Bicarbonate (mmol/L)
(22–29)
15.4 (4.7–26) 11.7–18.5
Base excess (24 to +2) 28.0 (226.9–2.1) 213.1 to 24.5
Serum creatinine (mmol/L)
(44–88)
44 (27–676) 36.8–51.9
Creatinine clearancea
(mL/min/1.73 m2)
85.8 (5.0–128.7) 70.7–101.4
MUAC, mid-upper arm circumference.
aEstimated according to age using the equations of Schwartz et al.26,27
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The population model therefore identified a standardized oral
CL in an adult weighing 70 kg of 42.7 L/h, and found that oral CL
was linearly and positively related to sodium concentration. The
model described an increase (or decrease) in oral CL by 3.7% for
every 1 mmol/L increase (or decrease) in the serum sodium con-
centration from the median value of 136 mmol/L. The standar-
dized oral CL fell by 28% to 30.6 L/h/70 kg in patients in the
‘high-risk’ category. The standardized oral V estimate was
372 L/70 kg and changed by 2.9% for every 1 mmol/L change
in the serum sodium concentration from 136 mmol/L.
All three validation methods indicated that the model pro-
vided a satisfactory description of the data. Figure 2 shows
good agreement between the measured concentrations and
the concentrations predicted by both the population pharmaco-
kinetic model (r2¼0.659) and the individual parameter esti-
mates (r2¼0.971). The pcVPC presented in Figure 3 shows that
the population model was able to describe the distribution of
the raw concentration data, and the npde check confirmed a
normal distribution around each individual observation within
the simulated dataset.
Table 3 summarizes the individual Bayes’ estimates of the
pharmacokinetic parameters and derived estimates of Cmax,
Tmax, t12 and AUC0 – 24. Oral CL had a median of 0.98 L/h/kg in
patients in the low and intermediate categories, and 0.67 L/h/kg
in high-risk patients. There was a wide variability in the individual
estimates of AUC0 – 24, which ranged from 7.9 to 61 mg.h/L.
Median estimates of AUC0 – 24 were higher in patients in the high-
risk category at 29.7 mg.h/L compared with 20.5 mg.h/L in the
low and intermediate categories.
Monte Carlo simulations
The percentage of simulated patients who achieved an
AUC0 – 24/MIC ratio of≥125 at each MIC value with the three cipro-
floxacin daily dosage regimens is presented in Figure 4. With
20 mg/kg/day, only 76% of patients would be expected to
achieve the target AUC0 – 24/MIC ratio if the MIC was 0.125 mg/L.
However, with daily doses of 30 and 45 mg/kg, the percentages
increased to 95% and 99%, respectively. Consequently, the phar-
macokinetic/pharmacodynamic breakpoint for Gram-negative
organisms was ,0.06 mg/L for the study dose of 20 mg/kg/day,
and ,0.125 mg/L for doses of 30 and 45 mg/kg/day. The target
AUC0 – 24/MIC ratio was achieved in ,5% of patients with all
dosage regimens if the MIC was .1 mg/L. When the results were
integrated with the MIC distribution for each organism, the CFR
was .80% with all three daily dosage regimens for E. coli and
Salmonella spp., and was 80% for K. pneumoniae with a dose of
30 mg/kg/day (Table 4). CFR values for P. aeruginosa were ,70%
for all doses tested.
Discussion
This study examined the population pharmacokinetics of cipro-
floxacin following oral doses of 10 mg/kg given 12 hourly on
the day of admission to a group of 52 paediatric patients with
severe malnutrition. Since the study was designed purely to
investigate ciprofloxacin pharmacokinetics and not efficacy, all
patients also received standard therapy for malnutrition and
for sepsis on admission. Patient weight, high risk of mortality
and serum sodium concentration were the main factors that
influenced the concentration–time profile of ciprofloxacin in
this patient group. Estimates of AUC24 ranged from 8 to
61 mg.h/L, indicating that an AUC/MIC ratio ≥125 would only
be achieved in all patients studied if the MIC was ,0.06 mg/L.
Sparse sampling was necessary due to the nature of the
population. The sampling windows covered different sections of
the 12 h dosage interval; additional trough concentrations
measured after the second dose were available from 16 patients.
The observed Cmax concentrations ranged from 0.6 to 4.5 mg/L.
Table 2. Parameter estimates arising from the final population model describing the pharmacokinetics of oral
ciprofloxacin in malnourished children
Parameter Population estimate Bootstrap estimate Bootstrap 95% CI
u1 42.7 42.5 37.0–49.3
u2 0.0368 0.0361 0.0217–0.0446
u3 20.283 20.285 20.412 to 20.118
u4 372 367 316–429
u5 0.0291 0.0282 0.0155–0.0388
u6 2.97 3.44 1.32–8.86
u7 0.742 0.792 0.168–0.924
BSV CL 38.1 37.8 28.7–45.8
BSV V 43.0 42.9 32.4–51.8
BSV ka 102 110 56–159
Residual error Additive (SD) 0.0273 0.0278 0.0041–0.0438
Proportional (%CV) 18.6 17.8 14.0–22.6
Structural model: TVCL¼u1×(WT/70)0.75×[1+u2×(Na+ – 136)]×[1+u3×(high risk)]; TVV¼u4×(WT/70)×[1+u5×(Na+ –
136)]; TVKA¼u6; ALAG¼u7.
Abbreviations: BSV, between-subject variability expressed as a % coefficient of variation; CL, oral clearance; V, oral volume
of distribution; TVCL, typical value of oral clearance (L/h); TVV, typical value of oral volume of distribution (L); TVKA, typical
value of the absorption rate constant (ka) (1/h); ALAG, absorption lag time (h); WT, body weight (kg); Na+, serum sodium
concentration (mmol/L).
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This range is lower than the values averaging 8.4 mg/L reported
by Schaefer et al.18 following intravenous doses of 10 mg/kg to
paediatric patients with cystic fibrosis, but is consistent, when
corrected for dose, with their range of 2.5–5 mg/L (mean
3.5 mg/L) achieved with an oral dose of 15 mg/kg. In contrast,
despite using a higher dose of 15 mg/kg, Peltola et al.19 observed
similar values of Cmax (0.5–5.3 mg/L) when they administered
ground tablets in water and mean Cmax values of 2–2.7 mg/L
following an oral suspension of 10 mg/kg.33 The observed varia-
bility in Cmax and Tmax (1–5 h) in the present study may reflect a
combination of variable oral bioavailability and the sampling
strategy. One limitation of the present study was that most
samples were taken ≥2 h after the dose and the Cmax may
have already been attained. Peak concentrations were typically
observed at 1–2 h in previous studies.19,33 The observed Cmax
measurements suggest that MIC values ,0.1 mg/L would ideally
be necessary to consistently achieve Cmax/MIC ratios of .10, as
recommended by MacGowan et al.34
The concentration–time data were adequately described by
first-order absorption with lag and a monoexponential decline.
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Figure 2. Observed versus population (a) and individual (b) predicted concentrations of ciprofloxacin in malnourished infants based on the final
population model. The thin line represents the line of identity; the thick line represents the linear regression line.
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Figure 3. Prediction-corrected visual predictive check of the final model
describing the pharmacokinetics of oral ciprofloxacin in infants with
malnutrition. The solid line represents the median of the raw data, the
dotted lines are the 10th and 90th percentiles of the raw data, and
the shaded areas are the 90% confidence intervals of the 10th, 50th
and 90th percentiles of the 1000 simulations based on the final model.
Table 3. Summary of individual ciprofloxacin pharmacokinetic
parameter estimates obtained in 52 children with severe malnutrition
Variable n Mean SD Median Minimum Maximum
CL(L/h) 52 7.43 3.54 7.19 1.83 17.1
CL(L/h/kg) 52 1.02 0.52 0.87 0.32 2.54
CL (L/h/kg) low/
intermediate risk
36 1.14 0.53 0.98 0.46 2.54
CL (L/h/kg) high risk 16 0.77 0.41 0.67 0.32 1.53
V (L/kg) 52 5.47 2.69 4.49 2.14 14.2
t1
2
(h) 52 3.97 1.38 3.78 2.01 9.04
Observed Tmax (h) 52 2.77 1.08 3.00 1.00 5.17
Model-predicted
Tmax (h)
52 1.91 0.58 1.79 1.09 3.85
Observed Cmax (mg/
L)
52 1.68 0.79 1.71 0.58 4.52
Model-predicted
Cmax (mg/L)
52 1.51 0.60 1.50 0.61 3.56
AUC0 – 24 (mg.h/L) 52 24.8 12.4 22.4 7.9 61.3
AUC0 – 24 (mg.h/L)
low/intermediate
risk
36 21.1 8.8 20. 5 7.9 43.4
AUC0 – 24 (mg.h/L)
high risk
16 32.9 15.5 29.7 13.1 61.3
Abbreviations: CL, oral clearance; V, oral volume of distribution; t1
2
,
elimination half-life; Tmax, the time of the maximum concentration;
AUC0 – 24, the steady-state 24 h AUC.
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Studies following the intravenous administration of ciprofloxacin
have identified a biexponential decline with a short distribution
half-life of 10–30 min,16 – 18,35,36 but the sparse sampling sche-
dule in the present study precluded the identification of a distri-
bution phase. The population model indicated a rapid absorption
of ciprofloxacin with an estimated half-life of 14 min after a lag
of 45 min. Previous population analyses in paediatric patients
reported shorter or similar absorption lag times, but rates of
absorption were slower, with half-lives ranging from 30 to
96 min.16 – 18 In contrast, Peltola et al.,19 who also used ground
tablets, reported mean absorption half-lives of 24 min in
infants up to 14 weeks old and 17 min in children aged
1–5 years. Both the present and previous population studies
identified wide variability in the absorption rate, with BSV
estimates ranging from 50% to 103%.16,17
Rajagopalan and Gastonguay17 reported a standardized
clearance of 30.3 L/h/70 kg in paediatric patients aged 14 weeks
to 17 years. Correcting for their bioavailability estimate of
61% gives an oral clearance of 49.7 L/h/70 kg, which is similar
to the value of 42.7 L/h/70 kg obtained in the present
study. Both results are reasonably consistent with values of
40–70 L/h reported in adults with normal renal function.37 – 39
Individual weight-corrected oral CL estimates were in the
range 0.3–2.5 L/h/kg in the present study and were similar to
the CL values reported by Rajagopalan and Gastonguay17 (0.2–
1.3 L/h/kg), when corrected for bioavailability (0.3–2.2 L/h/kg),
and the oral CL observed by Peltola et al.33 (1–1.5 L/h/kg). The
population model developed by Payen et al.16 predicts an oral
clearance increasing from 2 to 20 L/h over the age range
covered in the present study. These values are again consistent
with the present observations of 1.8–17 L/h. These findings
suggest that oral CL is similar in this population of malnourished
children to those reported in children without malnutrition.
Since there was no intravenous ciprofloxacin dose given, oral
bioavailability could not be determined directly from this study.
However, the similarity between the estimates of oral CL in the
present study with the results from previous studies suggests
that bioavailability may also be similar. Ciprofloxacin is generally
well absorbed, with a typical bioavailability of 70% in adults15
and 60%–70% in children.16 – 18,40 Rubio et al.40 reported a lower
bioavailability in children with cystic fibrosis aged 5–12 years
(68%) compared with those aged 13–17 years (95%), but this
age effect was not observed in the other studies. The formulation
that was used in the present study, i.e. tablets reformulated into a
suspension with water, has practical advantages over the com-
mercial oral suspension33 as it is much cheaper and easy to
prepare on site.
Another major aim of this study was to evaluate the impact
of feeding on oral clearance. Both milk and divalent cations
(such as magnesium and other minerals included in the nutri-
tional milk) have been reported to chelate quinolones and
reduce the oral bioavailability of ciprofloxacin.41 – 43 Since most
children are managed in resource-poor healthcare settings with
a limited number of healthcare personnel, it is both impractical
and difficult to ensure that the feeding times are synchronized
around the drug administration times. Consequently, a signifi-
cant proportion of children are likely to receive ciprofloxacin con-
comitantly with food and a reduction in bioavailability could
compromise efficacy. Although the preliminary analysis found
an increase in oral clearance in patients who received ciproflox-
acin with feeding, the objective function value only fell by 4.5
points, indicating a weak effect. In the final model, no influence
of feeding was identified. Thirteen of the 16 patients who were
given ciprofloxacin with food were in the low/intermediate-risk
category, which was associated with higher oral CL and lower
AUC estimates. The influence of risk may therefore have con-
founded the identification of a food effect, if one existed. Conver-
sely, if food was important, it may have enhanced the apparent
influence of risk in the model. The lack of a clear influence of
feeding on absorption is a positive finding. If a significant inter-
action had been observed, then the future use of this antimicro-
bial would have been compromised by the regular feeding
patterns required, and possible variability in the gut motility
and gastric emptying in children with severe malnutrition.
Dehydration and shock were initially found to influence oral CL
when examined alone, but both were related to other factors that
had a more powerful effect. Of the 16 patients in the high-risk cat-
egory, 12 had dehydration (of whom 11 had diarrhoea) and 6 had
shock. ‘High risk’ therefore accounted for both of these factors and
only sodium concentration provided an additional improvement in
the fit of the model to the data. An unexpected finding was the
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Figure 4. Percentage probability of achieving a target AUC0 – 24/MIC
ratio ≥125.
Table 4. Cumulative fraction of predicted response to achieve the target
AUC0 – 24/MIC ratio for three ciprofloxacin dosage regimens against
strains of Salmonella spp., P. aeruginosa, K. pneumoniae and E. coli
Organism
Target AUC0 – 24/
MIC ratio
Cumulative fraction of predicted
response (%)
20 mg/kg/
day
30 mg/kg/
day
45 mg/kg/
day
Salmonella spp. 125 96 98 99
P. aeruginosa 125 43 55 64
K. pneumonia 125 76 80 83
E. coli 125 85 87 88
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lack of an effect of renal function on oral CL, since ciprofloxacin CL
is known to decrease in renal impairment.37 – 39,44 However, the
only patient in the group with overt renal failure (creatinine con-
centration 676 mmol/L) was also categorized as high risk. This indi-
vidual had one of lowest estimates of oral CL at 1.8 L/h (0.33 L/h/kg).
Apart from this one individual, no other patient had severe renal
impairment; the highest serum creatinine concentration in other
patients was 95 mmol/L. Interestingly, another patient in the high-
risk category had a similar and very low oral CL (0.32 L/h/kg),
despite a creatinine concentration of 76 mmol/L. The t1
2
of cipro-
floxacin is 3–5 h in adults with normal renal function.37,38,44
Similar values have been found in previous studies in infants and
young children16,33,45 and in the present study, where t1
2
had a
median of 3.8 h and ranged from 2 to 9 h.
Although children in the high-risk category (including children
with impaired consciousness, shock and hypoglycaemia) had sig-
nificantly lower estimates of oral CL, individual estimates varied
widely in both groups (Table 3). ‘High risk’ children represent
the most critically ill cases, where both the logistics of adminis-
tration and gut absorption of oral microbiological agents are
likely to be compromised. Importantly, this finding highlights
the need for parenteral agents for the most critically ill, for
which third-generation cephalosporins are likely to be the most
appropriate. We have previously shown delayed uptake and
reduced clearance of gentamicin following an intramuscular
dose of 7.5 mg/kg in children with severe malnutrition compli-
cated by septic shock.10
The finding that low sodium concentration is associated with a
reduced oral CL is also of interest. Hyponatraemia in severe malnu-
trition has been postulated to be due to ‘adaptive reduction’ where
normal homeostatic cellular ATPase and sodium potassium
pumps are faulty, resulting in low sodium due increased extra-
cellular water.46,47 The reasons why low sodium is associated
with lower estimations of oral CL and oral V are not clear, but
although statistically significant, the inclusion of this factor only
reduced BSV in oral CL by 6% and BSV in oral V by 4%, so it had
a weak effect overall and may be an incidental finding.
The standardized estimate of oral V (372 L/70 kg) was
similar to that reported by Forrest et al.37 in adult patients
with normal renal function (321 L/1.73 m2), but higher than
the estimate of volume of distribution at steady state (Vss)
obtained by Rajagopalan and Gastonguay17 in paediatric
patients (240 L/70 kg when corrected for bioavailability). Indi-
vidual estimates of oral V ranged from 2 to 14 L/kg and the
median of 4.5 L/kg was more than twice the values of 2 L/kg
obtained by Schaefer18 and Payen16. Overall, these results indi-
cate that oral V is elevated in patients with malnutrition.
Similar results have been observed with gentamicin in malnour-
ished children—both higher mean and a wide interpatient varia-
bility.10 As with oral CL, a small but significant relationship
between oral V and sodium concentration was identified, with
higher sodium concentrations being associated with larger esti-
mates of oral V.
For fluoroquinolones in general, the ratio of the daily AUC to the
MIC (AUC/MIC) is likely to be the pharmacodynamic criterion most
predictive of clinical outcome.31 Forrest et al.31 found that the
probability of clinical cure in a group of seriously ill patients was
80% if the AUC/MIC was ≥125, but was only 42% below this
value and that faster eradication rates occurred if the AUC/MIC
was .250. The median estimate of steady-state AUC0 – 12 in the
present study (11.2 mg.h/L) is lower than the mean values of
13–19 mg.h/L reported by Lipman et al.48 following intravenous
doses of 10 mg/kg twice daily to paediatric patients with sepsis.
These differences probably reflect absorption, since correcting
for a bioavailability of 70% yields similar results to the present
study (predicted oral AUC0 – 12 range 9–13 mg.h/L). Even with
the higher AUC, Lipman et al. recommended increasing the dose
to 10 mg/kg 8 hourly to obtain AUC/MIC values of 100–150 for
organisms with MICs .0.3 mg/L.45 Estimates of AUC0 – 24 in the
present study ranged from 8 to 61 mg.h/L. The individual results
indicated that only 12% of the study patients would achieve an
AUC/MIC ≥125 if the MIC of the organism was 0.3 mg/L and 0%
if it was 0.5 mg/L. Monte Carlo simulations produced slightly
higher results (24% and 2%, respectively). Using a range of MIC
values, it was found that a dose of ≥30 mg/kg per day would be
required to achieve an AUC/MIC of ≥125 in .90% of patients if
the MIC was 0.125 mg/L and that an MIC of ,0.06 mg/L was
necessary to achieve satisfactory AUC/MIC values with a dose of
20 mg/kg/day. Using internationally derived distributions of the
MICs of a range of organisms, including the most common isolates
in children with severe malnutrition complicated by invasive bac-
terial disease, a dose of 20 mg/kg/day was sufficient for most iso-
lates of E. coli and Salmonella spp., but 30 mg/kg/day would be
necessary to treat Klebsiella infections. Even with higher doses of
45 mg/kg/day, targets for P. aeruginosa could only be achieved
in 64% of cases.
Similar problems of underdosing have also been identified
in adults. Standard intravenous doses of 400 mg twice daily
yielded inadequate AUC/MIC and Cmax/MIC ratios in critically
ill patients unless the MIC was ,0.25 mg/L.36 Simulations con-
ducted by Montgomery et al.35 demonstrated that for an MIC
of 0.5 mg/L, 400 mg 12 hourly would only achieve an AUC/MIC
≥125 in 15% of adults with cystic fibrosis and that an increase
to 600 mg 8 hourly would be required to achieve .90%
success. If the dose used in the present study was increased
to 15 mg/kg 8 hourly and assuming no change in bioavailabil-
ity, the probability of achieving an AUC/MIC ≥125 would
increase to 83% for an MIC of 0.3 mg/L and 32% for an MIC
of 0.5 mg/L. However, 37% of patients would then reach
daily AUCs .60 mg.h/L. These values are higher than the
mean daily AUCs reported following the administration of
intravenous high-dose ciprofloxacin (400 mg 8 hourly) to criti-
cally ill adults48 and it is possible that such high exposure
would increase the risk of toxicity in such patients.
Conclusions
The pharmacokinetics of oral ciprofloxacin in children with severe
malnutrition is influenced by weight, serum sodium concen-
tration and the risk of mortality, but there was high variability
in the clearance and rate of absorption. Oral ciprofloxacin
absorption was unaffected by the simultaneous administration
of nutritional feeds. An oral dose of 10 mg/kg twice daily
should be effective against E. coli and Salmonella spp., but a
higher dose of 10 mg/kg three times a day would be rec-
ommended for K. pneumoniae. Oral ciprofloxacin is unlikely to
be an effective treatment for P. aeruginosa. Irrespective of the
bacterial pathogen, patients with severe illness, at high risk of
mortality, should initially receive intravenous antibiotics.
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